Cutler Group LP Fate Therapeutics Inc Transaction History

Cutler Group LP

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2022 Apr 14, 2022	SELL	$29.67 - $60.28 $6,201 - $12,598	-209 Closed	0 $0
Q4 2021 Jan 18, 2022	SELL	$47.84 - $64.34 $95,680 - $128,680	-2,000 Reduced 90.54%	209 $12,000
Q3 2021 Oct 26, 2021	BUY	$59.27 - $95.73 $122,036 - $197,108	2,059 Added 1372.67%	2,209 $130,000
Q1 2021 Apr 26, 2021	SELL	$72.16 - $117.4 $88,756 - $144,402	-1,230 Reduced 89.13%	150 $12,000
Q4 2020 Jan 21, 2021	BUY	$38.09 - $100.95 $3,047 - $8,076	80 Added 6.15%	1,380 $125,000
Q2 2020 Jul 22, 2020	BUY	$20.21 - $35.23 $12,126 - $21,137	600 Added 85.71%	1,300 $44,000
Q4 2019 Feb 06, 2020	SELL	$13.39 - $20.73 $4,017 - $6,219	-300 Reduced 30.0%	700 $13,000
Q2 2018 Aug 10, 2018	BUY	$9.16 - $13.48 $9,160 - $13,480	1,000 New	1,000 $11,000

175

115M

53.7K

Ticker FATE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 97,000,304
Market Cap $215M
Description
Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. Its NK- and T-cell immuno-oncology programs under development include FT516 for the treatment of acute myeloid leukemia (AML) B-cell lymphoma, and advanced solid tumor; FT596 to treat B-cell...

Get notified when there are updates to the investment portfolio of Cutler Group LP, based on Form 13F filings with the SEC.

Stay updated on Cutler Group LP with notifications on news.